26. Centers for Disease Control and Prevention. Vital signs:
walking among adults—United States, 2005 and 2010.
MMWR Morb Mortal Wkly Rep 2012;61:595–601.
27. Calle EE, Rodriguez C, Walker-;urmond K, ;un MJ.
Overweight, obesity, and mortality from cancer in a
prospectively studied cohort of U.S. adults. N Engl J
Med 2003;348:1625–38.
28. Ballard-Barbash R, Friedenreich CM, Courneya KS,
Siddiqi SM, Mc Tiernan A, Alfano CM. Physical
activity, biomarkers, and disease outcomes in cancer
survivors: a systematic review. J Natl Cancer Inst
2012;104:815–40.
29. Cao Y, Ma J. Body mass index, prostate cancer-speci;c
mortality, and biochemical recurrence: a systematic
review and meta-analysis. Cancer Prev Res (Phila)
2011;4:486–501.
30. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B,
Bouvard V, et al. A review of human carcinogens—part
D: radiation. Lancet Oncol 2009;10:751–2.
31. Koh HK, Geller AC, Miller DR, Grossbart TA, Lew RA.
Prevention and early detection strategies for melanoma
and skin cancer. Current status. Arch Dermatol
1996;132:436–43.
32. Parkin DM, Mesher D, Sasieni P. 13. Cancers
attributable to solar (ultraviolet) radiation exposure in
the UK in 2010. Br J Cancer 2011; 105(Suppl 2):S66-9.
33. Wehner MR, Chren MM, Nameth D, Choudhry A,
Gaskins M, Nead KT, et al. International Prevalence of
indoor tanning: a systematic review and meta-analysis.
JAMA Dermatol 2014;150:390–400.
34. Boniol M, Autier P, Boyle P, Gandini S. Cutaneous
melanoma attributable to sunbed use: systematic
review and meta-analysis. BMJ 2012;345:e4757.
35. van der Pols JC, Williams GM, Pandeya N, Logan V,
Green AC. Prolonged prevention of squamous cell
carcinoma of the skin by regular sunscreen use. Cancer
Epidemiol Biomarkers Prev 2006;15:2546–8.
36. Green AC, Williams GM, Logan V, Strutton GM.
Reduced melanoma a;er regular sunscreen use:
randomized trial follow-up. J Clin Oncol 2011;29:257–
63.
37. Centers for Disease Control and Prevention. Sunburn
and sun protective behaviors among adults aged 18-
29 years—United States, 2000–2010. MMWR Morb
Mortal Wkly Rep 2012;61:317–22.
38. Centers for Disease Control and Prevention. Use of
indoor tanning devices by adults—United States, 2010.
MMWR Morb Mortal Wkly Rep 2012;61:323–6.
39. Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH,
Hawkins J, et al. Youth risk behavior surveillance—
United States, 2011. MMWR Surveill Summ 2012;61: 1–
162.
40. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El
Ghissassi F, et al. A review of human carcinogens—Part
B: biological agents. Lancet Oncol 2009;10:321–2.
41. Chang Y, Moore PS. Merkel cell carcinoma: a virus-
induced human cancer. Annu Rev Pathol 2012;7:123–44.
42. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F,
Forman D, et al. Global burden of cancers attributable
to infections in 2008: a review and synthetic analysis.
Lancet Oncol 2012;13:607–15.
43. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW,
Holmberg SD. ;e increasing burden of mortality from
viral hepatitis in the United States between 1999 and
2007. Ann Intern Med 2012;156:271–8.
44. Accelerating HPV vaccine uptake: urgency for action to
prevent cancer. A report to the President of the United
States from the President’s Cancer Panel. Bethesda
(MD): National Cancer Institute; 2014.
45. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K,
Aboyans V, et al. Global and regional mortality from
235 causes of death for 20 age groups in 1990 and 2010:
a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 2012;380:2095–128.
46. Ioannou GN. Hepatitis B virus in the United States:
infection, exposure, and immunity rates in a nationally
representative survey. Ann Intern Med 2011;154:319–28.
47. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM,
Ward JW, McQuillan GM, et al. Chronic hepatitis C
virus infection in the United States, National Health
and Nutrition Examination Survey 2003 to 2010. Ann
Intern Med 2014;160:293–300.
48. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M,
Smith BD, Lesesne SB. Forecasting the morbidity and
mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig
Liver Dis 2011;43: 66–72.
49. Centers for Disease Control and Prevention. Human
papillomavirus-associated cancers—United States,
2004–2008. MMWR Morb Mortal Wkly Rep
2012;61:258–61.
50. Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal
PA, Golub TR, et al. AACR Cancer progress report
2012. Clin Cancer Res 2012;18:S1–100.
51. Yang JC, Lu CW, Lin CJ. Treatment of infection: current
status and future concepts. World J Gastroenterol
2014;20:5283–93.
52. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM,
et al. Decreased incidence of hepatocellular carcinoma
in hepatitis B vaccinees: a 20-year follow-up study. J
Natl Cancer Inst 2009;101:1348–55.
53. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ,
Yuen H, et al. Lamivudine for patients with chronic
hepatitis B and advanced liver disease. N Engl J Med
2004;351:1521–31.
54. LeFevre ML. Screening for hepatitis B virus infection in
nonpregnant adolescents and adults: U.S. Preventive
Services Task Force recommendation statement. Ann
Intern Med 2014;161: 58–66 55. Liang TJ, Ghany
MG. ;erapy of hepatitis C–back to the future. N Engl
J Med 2014;370:2043–7.
56. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y,
Holtzman D, Teo CG, et al. Recommendations for the
REFERENCES